secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019958
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience Q1 revenue up 353% to $1.58M, net loss narrows to $1.6M
-----------------------------------------------------------------------

- Revenue $1,576,286, up 353% YoY from $348,025; clinic revenue up 417% to $1.54M.
- Net loss $(1.6) million vs $(2.6) million; Adjusted EBITDA improved to $(0.5) million from $(1.7) million.
- Merger with NAYA Biosciences pending; shareholders to receive 7.3333 INVO shares per NAYA share (~18.15M shares total).
- NAYA has provided $906k in Series A Preferred Stock financing towards $5M minimum condition for merger.
- Management expects to reach break-even on current operations (ex-merger) in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer